Encompass Health Co. (NYSE: EHC) is expected to report quarterly sales of $ 1.32 billion


Equity research analysts expect Encompass Health Co. (NYSE: EHC) to report $ 1.32 billion in revenue for the current quarter, according to Zacks Investment Research. Five analysts have estimated Encompass Health’s earnings. The highest sales estimate is $ 1.32 billion and the lowest is $ 1.31 billion. Encompass Health reported sales of $ 1.17 billion in the same quarter last year, suggesting a positive year-over-year growth rate of 12.8%. The company is expected to release its next quarterly results after the market closes on Wednesday, October 27.

On average, analysts expect Encompass Health to report annual sales of $ 5.18 billion for the current year, with estimates ranging from $ 5.16 billion to $ 5.21 billion. . For the next fiscal year, analysts predict the company will post revenue of $ 5.61 billion, with estimates ranging from $ 5.53 billion to $ 5.74 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sales analysts who cover Encompass Health.

Encompass Health (NYSE: EHC) last reported its quarterly results on Monday, July 26. The company reported EPS of $ 1.17 for the quarter, beating consensus analysts’ estimates of $ 0.98 by $ 0.19. Encompass Health recorded a return on equity of 19.49% and a net margin of 7.83%. The company posted revenue of $ 1.29 billion in the quarter, compared to analysts’ estimates of $ 1.28 billion. In the same quarter of last year, the company posted earnings per share of $ 0.34. The company’s revenue grew 22.9% year-over-year.

A number of analysts recently commented on the company. Raymond James downgraded Encompass Health from an “outperformance” rating to a “strong buy” rating and raised his stock price target from $ 95.00 to $ 107.00 in a research note Monday August 2. Credit Suisse Group raised its price target on Encompass Health from $ 96.00 to $ 98.00 and gave the stock an “outperformance” rating in a research note on Thursday, July 29. Royal Bank of Canada raised its price target on Encompass Health from $ 102.00 to $ 104.00 and assigned the stock an “outperformance” rating in a research note on Thursday, July 29. Deutsche Bank Aktiengesellschaft raised its price target on Encompass Health from $ 104.00 to $ 110.00 and gave the stock a “buy” rating in a report released Thursday, July 29. Finally, the UBS Group assumed the coverage of Encompass Health in a report published on Thursday 23 September. They issued a “buy” note and a price target of $ 98.00 for the company. One analyst rated the stock with a sell rating, six issued a buy rating, and one gave the company a strong buy rating. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $ 98.88.

(A d)

Plant-based food technology stocks dominate its industry with sales of $ 60 million.

Several large investors have recently changed their holdings in EHC. Principal Financial Group Inc. increased its holdings of Encompass Health shares by 9.9% in the first quarter. Principal Financial Group Inc. now owns 780,559 shares of the company valued at $ 63,928,000 after acquiring an additional 70,509 shares last quarter. Pendal Group Limited increased its stake in Encompass Health shares by 24.6% during the first quarter. Pendal Group Limited now owns 4,001 shares of the company valued at $ 328,000 after acquiring 791 additional shares during the last quarter. Schroder Investment Management Group increased its holdings of Encompass Health shares by 12.9% in the first quarter. Schroder Investment Management Group now owns 1,251,115 shares of the company valued at $ 102,467,000 after acquiring an additional 142,797 shares in the last quarter. Warren Averett Asset Management LLC purchased a new position in Encompass Health shares during the first quarter valued at $ 391,000. Finally, Invst LLC purchased a new position in Encompass Health shares during the first quarter valued at $ 480,000. Hedge funds and other institutional investors hold 90.64% of the company’s shares.

EHC shares opened at $ 73.44 on Tuesday. The stock has a fifty-day moving average of $ 77.34 and a 200-day moving average of $ 78.98. Encompass Health has a 52-week low of $ 60.51 and a 52-week high of $ 89.68. The company has a market cap of $ 7.31 billion, a price / earnings ratio of 19.13, a PEG ratio of 0.99 and a beta of 1.10. The company has a quick ratio of 1.07, a current ratio of 1.07, and a debt ratio of 1.43.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 15. Shareholders of record on Friday October 1 will receive a dividend of $ 0.28. The ex-dividend date for this dividend is Thursday, September 30. This represents a dividend of $ 1.12 on an annualized basis and a return of 1.53%. Encompass Health’s dividend payout ratio (DPR) is 38.75%.

About Encompass Santé

Encompass Health Corp. provides post-acute health care services. It operates through the Inpatient Rehabilitation and Home and Palliative Care segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitation treatment and care to patients recovering from stroke and other neurological disorders, heart and lung disorders, brain and spinal cord injuries. , complex orthopedic disorders and amputations.

Featured story: what does it take to own or trade cryptocurrency?

Get a Free Copy of Zacks’ Research Report on Encompass Health (EHC)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Encompass Health Revenue History and Estimates (NYSE: EHC)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Encompass Health now?

Before you consider Encompass Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Encompass Health was not on the list.

While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Leave A Reply